Evercore ISI downgraded Theravance Biopharma to In Line from Outperform with an $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TBPH:
- Viatris, Theravance announce top-line results from YUPELRI Phase III trial
- Viatris, Theravance Biopharma announce results from YUPELRI
- Theravance Biopharma reports Q3 EPS (17c), consensus (21c)
Questions or Comments about the article? Write to editor@tipranks.com